



December 7, 2017

Revance Announces Pricing of Public Offering of Common Stock

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the pricing of an underwritten public offering of 5,338,709 shares of its common stock at a price to the public of \$31.00 per share. In the offering, the Company will issue and sell 4,838,709 shares and certain stockholders of the Company (the "Selling Stockholders") will sell 500,000 shares. Revance and the Selling Stockholders have granted the underwriters a 30-day option to purchase up to an aggregate of additional 800,806 shares from the Company and the Selling Stockholders. The gross proceeds to the Company from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately \$150 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company will not receive any proceeds from the sale of the shares by the Selling Stockholders. The offering is expected to close on or about December 11, 2017, subject to customary closing conditions. The Company intends to use the net proceeds received from its offering of common stock for general corporate purposes, including clinical trial and related expenses, research and development expenses, general and administrative expenses, and capital investments.

Goldman Sachs & Co. LLC and Cowen are acting as book-running managers, Barclays is acting as joint lead manager, and Cantor Fitzgerald & Co., William Blair & Company, L.L.C. and SunTrust Robinson Humphrey are acting as co-managers for the proposed offering.

A shelf registration statement relating to the securities described above was filed with the Securities and Exchange Commission on December 5, 2017 and automatically became effective the same day. The offering will be made only by means of a prospectus supplement. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering may be obtained by contacting Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectusgroup-ny@ny.email.gs.com; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Revance Therapeutics, Inc.

Revance is a clinical-stage biotechnology company focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. Revance is leveraging its proprietary portfolio of botulinum toxin type A compounds, formulated with its patented and proprietary peptide technology, to address unmet needs in large and growing neurotoxin markets.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Revance's expectations regarding the completion of the proposed public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not Revance will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Revance will be able to complete the proposed public offering on the anticipated terms, or at all. Revance will need to raise additional capital to fund its operations and may be unable to raise capital when needed, which would force Revance to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the proposed offering, Revance and its business can be found under the heading "Risk Factors" in the preliminary prospectus supplement (and documents incorporated by reference therein) related to the proposed public offering filed with the

Securities and Exchange Commission. Revance expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.



View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20171207005534/en/>

INVESTORS

Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
jherbert@revance.com

or

Burns McClellan, Inc.:
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com

or

MEDIA

General Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com

or

Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com

Source: Revance Therapeutics, Inc.

News Provided by Acquire Media